Esperion Q1 revenue $137.7M (+467% YoY), net income of $61.0M; FDA label expansion expands market

Esperion Therapeutics, Inc.

2024-Q1 EPS reported $0.34 revenue$137,735,000

Total revenue $137.7M vs $24.3M YoY; U.S. net product revenue $24.8M (+46% YoY).
Net income of $61.0M ($0.36 basic EPS) vs net loss of $61.7M in Q1 2023.
FDA approved label expansions for NEXLETOL/NEXLIZET to add CV risk reduction and use without statin.
Cash balance $226.6M at quarter end, up from $82.2M at Dec 31, 2023.
FY 2024 operating expense guidance maintained at $225M-$245M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Esperion Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $137.7 million.

Period: first quarter ended March 31, 2024
Revenue: $137.7 million
Result: reported results

Exact text from the filing

Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-020841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.